Tovinontrine not checked
Imara, Inc. · Cardurion Pharmaceuticals, Inc. · IMR-687
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Sickle Cell Disease
- Main trialPhase 2
- “This is an open-label extension study of IMR-687 in adult patients who completed Imara's blinded Phase 2a study (IMR-SCD-102). The open-label extension study will evaluate long-term safety and tolerability.”In the company’s words, NCT04053803 on ClinicalTrials.gov
- Other names
- IMR-687
Other drugs for Sickle Cell Disease
- 20vPCVSanofi · Phase 3
- Pneumococcal Conjugate VaccineSanofi · Phase 3
- CTX001Vertex Pharmaceuticals · Phase 3
- L-citrullineAsklepion Pharmaceuticals, LLC · Phase 3
- RilzabrutinibSanofi · Phase 3
- EtavopivatNovo Nordisk · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Mar 2025 | An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia | |
| Phase 2Completed | 28 Aug 2020 | A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) | |
| Phase 2Terminated | 2 Mar 2022 | A Study of IMR-687 in Subjects With Sickle Cell Disease | |
| Phase 2Terminated | 11 Mar 2022 | A Study of IMR-687 in Subjects With Beta Thalassemia | |
| Phase 2Withdrawn | Sep 2023 | Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction | |
| Phase 2Completed | 2 Sep 2025 | Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF) | |
| Phase 2Completed | 10 Oct 2025 | A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF) | |
| Phase 1Completed | 8 Jul 2017 | A Study of IMR-687 in Healthy Adult Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026